Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study by Majoor, CJ et al.
Majoor et al. Respiratory Research 2014, 15:14
http://respiratory-research.com/content/15/1/14RESEARCH Open AccessEvaluation of coagulation activation after
Rhinovirus infection in patients with asthma and
healthy control subjects: an observational study
Christof J Majoor1*, Marianne A van de Pol1,2, Pieter Willem Kamphuisen8, Joost CM Meijers3, Richard Molenkamp4,
Katja C Wolthers4, Tom van der Poll5, Rienk Nieuwland6, Sebastian L Johnston9, Peter J Sterk1, Elisabeth HD Bel1,
Rene Lutter1,2 and Koenraad F van der Sluijs1,2,7Abstract
Background: Asthma exacerbations are frequently triggered by rhinovirus infections. Both asthma and respiratory
tract infection can activate haemostasis. Therefore we hypothesized that experimental rhinovirus-16 infection and
asthmatic airway inflammation act in synergy on the haemostatic balance.
Methods: 28 patients (14 patients with mild allergic asthma and 14 healthy non-allergic controls) were infected
with low-dose rhinovirus type 16. Venous plasma and bronchoalveolar lavage fluid (BAL fluid) were obtained before
and 6 days after infection to evaluate markers of coagulation activation, thrombin-antithrombin complexes, von
Willebrand factor, plasmin-antiplasmin complexes, plasminogen activator inhibitor type-1, endogenous thrombin
potential and tissue factor-exposing microparticles by fibrin generation test, in plasma and/or BAL fluid. Data were
analysed by nonparametric tests (Wilcoxon, Mann Whitney and Spearman correlation).
Results: 13 patients with mild asthma (6 females, 19-29 y) and 11 healthy controls (10 females, 19-31 y) had a
documented Rhinovirus-16 infection. Rhinovirus-16 challenge resulted in a shortening of the fibrin generation test
in BAL fluid of asthma patients (t = −1: 706 s vs. t = 6: 498 s; p = 0.02), but not of controls (t = −1: 693 s vs. t = 6:
636 s; p = 0.65). The fold change in tissue factor-exposing microparticles in BAL fluid inversely correlated with
the fold changes in eosinophil cationic protein and myeloperoxidase in BAL fluid after virus infection (r = −0.517
and −0.528 resp., both p = 0.01).
Rhinovirus-16 challenge led to increased plasminogen activator inhibitor type-1 levels in plasma in patients with
asthma (26.0 ng/mL vs. 11.5 ng/mL in healthy controls, p = 0.04). Rhinovirus-16 load in BAL showed a linear
correlation with the fold change in endogenous thrombin potential, plasmin-antiplasmin complexes and
plasminogen activator inhibitor type-1.
Conclusions: Experimental rhinovirus infection induces procoagulant changes in the airways of patients with
asthma through increased activity of tissue factor-exposing microparticles. These microparticle-associated
procoagulant changes are associated with both neutrophilic and eosinophilic inflammation. Systemic activation
of haemostasis increases with Rhinoviral load.
Trial registration: This trial was registered at the Dutch trial registry (www.trialregister.nl): NTR1677.
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It is increasingly recognized that inflammation and
haemostasis are interdependent and closely linked pro-
cesses that can stimulate each other [1,2]. Many chronic
inflammatory diseases, including inflammatory bowel
diseases [3,4], rheumatic arthritis [5,6], COPD [7-9], and
sarcoidosis [10], are associated with increased coagu-
lability of blood. This procoagulant state has also been
observed in the airways of patients with stable asthma
as reflected by increased levels of tissue factor (TF),
thrombin-antithrombin complexes (TATc) and the plas-
minogen activator inhibitor-1 (PAI-1), as well as decreased
levels of the natural anticoagulant protein C [11]. Local
activation of coagulation may be clinically relevant for
asthmatic individuals, because we have recently shown
that the risk of pulmonary embolism (PE) is increased in
severe asthma [12]. Recently a second study on pulmonary
embolism and asthma showed not only that there is an
increased risk to develop PE but that PE was associated
with disease exacerbations [13].
In addition to chronic inflammatory conditions of the
lung, viral and bacterial infections have been shown to
induce pulmonary coagulation as well [14]. For example,
elderly patients with proven respiratory viral infection
had activated coagulation, as shown by increased levels
of von Willebrand factor (vWF), plasmin-α2-antiplasmin
complexes (PAPc), D-dimer and endogenous thrombin
potential (ETP) [15]. In addition, respiratory infections
were a risk factor for venous thromboembolic events in
a large cohort from the general population [16].
Asthma exacerbations are most often caused by re-
spiratory viruses [17,18], in particular rhinovirus [19].
Whether rhinovirus induced airway inflammation syner-
gistically affects the haemostatic balance in patients with
asthma is as yet unknown.
We hypothesized that rhinovirus infection enhances
coagulation and reduces fibrinolysis in patients with
asthma to a larger extent than in healthy control sub-
jects. Therefore, the aim of the present study was to
determine the effect of experimental rhinovirus infection
on coagulation (TATc, TF-activity of microparticles,
D-dimer and ETP), endothelial activation (vWF) and
fibrinolysis (PAPc and PAI-1) in peripheral blood and
bronchoalveolar lavage (BAL) fluid of patients with mild
allergic asthma and healthy control subjects. The second
aim was to assess the relationship between coagulation
and fibrinolytic parameters and markers of airway inflam-
mation in BAL fluid.
Methods
Subjects
Patients with mild asthma had a doctor’s diagnosis of
asthma and had to meet the following criteria: baseline
FEV1 > 80% predicted, PC20 (methacholine) < 8.0 mg/ml,skin-prick test positive for at least one out of 12 common
aeroallergens. Healthy control subjects had the following
criteria: baseline FEV1 > 80% predicted, PC20 (metha-
choline) > 16.0 mg/ml, skin-prick test negative for 12 com-
mon aeroallergens. All volunteers were aged between 18
and 40 years, were non-smoking or had stopped smoking
more than 12 months ago with ≤ 5 pack years (PY), were
negative for neutralizing antibodies against rhinovirus type
16 and did not have concomitant disease or (chronic) in-
flammatory condition that would interfere with this study,
according to the judgment of a pulmonary physician. Pa-
tients with asthma were not allowed to use asthma medi-
cation other than short-acting β2-agonists within 2 weeks
prior to the start of this study until day 6 after rhinovirus
infection. Informed consent was obtained from each indi-
vidual before inclusion.
Design and procedure
In a prospective parallel design single center study all
volunteers were experimentally infected with rhinovirus
type 16 (RV16) as described previously [20], but now
with low-dose rhinovirus (10TCID50). In brief, upon re-
trieval of informed consent and subsequent screening,
volunteers who met the inclusion criteria for healthy
inviduals or volunteers who met the criteria for mild al-
lergic asthma patients underwent a bronchoscopy for
baseline measurements. One day later, volunteers were
experimentally infected with RV16, which has been
shown to cause mild common-cold symptoms in both
healthy individuals and stable allergic asthma patients
and to evoke a transient exacerbation of asthma symp-
toms. All volunteers were requested to report common
cold and asthma symptoms daily until day 14 after
rhinovirus challenge [20]. Diaries were collected at the
final visit. Venous plasma and BAL fluid were obtained
the day before and 6 days after infection. Before bronchos-
copy all volunteers had used short-acting β2-agonists.
Nasal swabs, brushes and BAL fluid to determine rhino-
virus infection by PCR were obtained the day before and
6 days after infection. Venous blood to check for serocon-
version was drawn at day 42. See Figure 1 for a flow chart
of the study. More details are provided in the Additional
files 1.
The study was approved by Medical Ethics Committee
of the Academic Medical Centre in Amsterdam, The
Netherlands. The study was registered at The Netherlands
Trial Register (no. 1677). Written informed consent was
obtained from all volunteers.
The primary objective of the study was to evaluate
tryptophan catabolism in patients with allergic asthma
and healthy subjects and the change in this metabolism
after experimental rhinovirus infection [21]. Coagulation
was defined as a secondary endpoint for this study.
Therefore dedicated frozen citrate plasma and BAL fluid
Figure 1 Study design (adapted from ref. [21]).
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sion for RV-16 after infection were analysed [21].
Measurement of coagulation parameters
Measurements of TATc (Siemens Healthcare Diagnostics,
Marburg, Germany), PAPc (DRG, Marburg, Germany)
and PAI-1 (Hyphen BioMed, Andrésy, France), were per-
formed by ELISA. D-dimer levels were determined with a
particle-enhanced immunoturbidimetric assay (Innovance
D-Dimer, Siemens Healthcare Diagnostics, Marburg,
Germany). vWF was determined by ELISA with a poly-
clonal rabbit anti-human vWF antibody (A0082) as catch-
ing antibody and a horse radish peroxidase-labeled rabbit
anti-human vWF antibody (P0226) as detecting antibody
(both from DAKO, Glostrup, Denmark).
The presence of coagulant TF-exposing microparticles
in BAL fluid was measured by a fibrin generation test
(FGT) in autologous vesicle-depleted pool plasma as
described before [22]. In brief, this assay determines the
intrinsic capacity of the procoagualant TF-exposing mi-
croparticles in any fluid. Microparticles are isolated from
the fluid by ultracentrifuge. After isolation the micro-
particles are added to autologous vesicle-depleted pool
plasma to initiate fibrin formation. The time to clot
formation decreases with increased procoagulant activity
of the TF-exposing microparticles in the investigated
fluid. The procoagulant activity of microparticles (time
to clot formation) was measured by a Spectramax micro-
plate reader [22]. ETP was assayed using the Calibrated
Automated Thrombogram®. This assay determines the
generation of thrombin in clotting plasma using a mi-
crotiter plate reading fluorometer (Fluoroskan Ascent,
ThermoLab systems, Helsinki, Finland) and Thrombino-
scope® software (Thrombinoscope BV, Maastricht, The
Netherlands). The assay was carried out as described by
Hemker et al. [23] and the Thrombinoscope® manual.
More details are provided in the Additional file 1.
Measurement of inflammatory parameters in BAL fluid
Leukocytes in BAL fluid were counted and differentiated
on Quick Diff stained cytospin preparations. IL-8 was
determined by Luminex according to the manufacturer's
protocol (single-plex IL-8 antibody and reagent kit fromBio-Rad Laboratories, Veenendaal, The Netherlands).
Myeloperoxidase (MPO) was measured by ELISA (Costar,
EIA/RIA high-binding plate) using a rabbit anti-MPO
(Dako A0398) as capture antibody and the biotinylated
antibody as detection antibody with a well-characterised
sample as MPO standard. Eosinophil cationic protein
(ECP) was measured by ELISA (Nunc, Maxisorp plate)
using a monoclonal mouse-anti-human ECP capture
antibody (clone 614, Diagnostics Development, Uppsala
Sweden), ECP standard (ImmunoCAP ECP Calibrator.
Phadia, Nieuwegein, The Netherlands) and a biotinylated
polyclonal rabbit-anti-human ECP detection antibody
(batch ECP03-091; Diagnostics Development, Uppsala,
Sweden). Both ELISAs were developed using streptavidin
poly-HRP (M2051, Sanquin, Amsterdam, The Netherlands)
and tetramethyl-benzidine (TMB, Merck, Darmstadt,
Germany).
Statistical analysis
Coagulation was defined as a secondary endpoint. These
endpoints were defined as the changes from baseline in
TATc, vWF, D-dimer, PAPc, PAI-1, and ETP in plasma
and changes from baseline in TATc, vWF, FGT, D-dimer,
PAPc, and PAI-1 in BAL fluid. Changes from baseline
were calculated by calculating the fold change, which is
the ratio of pre- and post-interventional scores (for which
the following formula was used: post-interventional score/
pre-interventional score). Comparisons between both time
points for each group were calculated by Wilcoxon signed
rank test. Fold changes between both groups were ana-
lyzed by Mann–Whitney U test. Spearman rho correla-
tions were used to determine associations between the
fold changes of coagulation and inflammatory markers in
BAL fluid. Linear correlations were calculated for the fold
changes of coagulation in plasma and BAL fluid and the
viral load detected in BAL-fluid. Differences were consid-
ered significant for all statistical tests at p-values less than
0.05. All reported p-values are two-sided. Analyses were
performed with SPSS 18.0 (Chicago, IL, USA).
Results
In total 28 volunteers (14 patients with mild asthma and
14 healthy controls) were included in the study. Out of
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mild asthma and 11 healthy control subjects had a posi-
tive PCR at day 6 (either in BAL fluid or in nasal swabs
or both) and/or a serologic conversion for RV16 at day
42. Two BAL fluid samples were excluded from the ana-
lysis as these samples contained >15% bronchial and
squamous epithelial cells. Therefore disruption of the
epithelial barrier and subsequent contamination of BAL
fluid with plasma cannot be excluded for these samples.
Clinical and virologic characteristics of patients and con-
trols are shown in Table 1.
Evaluation of haemostasis and fibrinolysis
Venous plasma
Measurements of haemostatic and fibrinolytic markers
in venous plasma at baseline and after viral infection are
shown in Table 2. Of the procoagulant markers TATc
was significantly higher in healthy control subjects as
compared to patients with mild asthma at baseline
(p = 0.02) as well as after viral infection (p = 0.03),
whereas D-dimer, ETP and the marker of endothelial acti-
vation, vWF, did not differ at both time points. RV16 did
not induce procoagulant changes in plasma as measured
by the calculated fold changes (Figure 2A–D).
The fibrinolytic marker PAP and PAI-1 did not differ
between both groups at baseline. Although the fold
changes of the fibrinolytic parameters did not change
significantly (Figure 2E and F), PAP levels were signifi-
cantly lower (p = 0.047) and PAI-1 levels significantly
higher (p = 0.04) after RV16 infection in asthma patients
than in healthy individuals.
BAL-fluid
Amongst the procoagulant markers (TATc, D-dimer), the
endogenous capacity of the TF-exposing microvesicles
(FGT) and the marker of endothelial activation (vWF) only
TATc and FGT were detectable in BAL-fluid (Table 3).Table 1 Demographic data of participants*
Healthy contr
Female, n (%) 10 (91
Age, years (range) 21 (19–
Oral anticonceptive use, n (%) 4 (36
PC20 (mg/ml), geometric mean (95% CI) >16
FENO (ppb), mean (SD) 23.3 (12
FEV1 % pred. (range) 102 (90–
pbFEV1, % pred. (range) 107 (98–
PCR-positive for RV16 on day 6, n (%) 9 (81
PCR-positive for RV16 on day 6 in BALf, n (%) 3 (27
RV16 neutralization on day 42, n (%) 9 (81
*see Additional file 1 for inclusion and exclusion criteria.
BALf, Bronchoalveolar lavage fluid; FEV1, Forced expiratory volume in 1 sec; FENO,
methacholine chloride to cause a 20 % falling in FEV1; RV16, Rhinovirus serotype 16TATc levels in BAL-fluid were not different between both
groups at baseline and after RV16 challenge nor did the
fold change from baseline differ between both groups.
However, FGT being similar in both groups at baseline,
shortened in patients with asthma after viral infection
(t = −1: 706 s vs. t = 6: 498 s; p = 0.02), but not in
healthy control subjects (t = −1: 693 s vs. t = 6: 636 s;
p = 0.65; Table 3) Change from baseline of FGT after
RV16 challenge did significantly differ between patients
with mild asthma and healthy control subjects (p = 0.04;
Figure 3A and B).
Of the fibrinolytic markers, only PAPc was detectable
in BAL-fluid. PAPc levels did not differ between both
time points nor did the fold change from baseline differ
between both groups.
Associations between coagulation and inflammatory
parameters
As compared to healthy control subjects, patients with
mild asthma had significantly higher levels of eosinophils
(Median 1.0% vs. 0.25%, resp. p < 0,01) and ECP (Median
286 pg/ml vs. 159 pg/ml, resp. p < 0,05) at both time-
points. Asthmatic individuals showed an increase in ECP
(Median 286 pg/ml to 507 pg/ml after viral infection,
p = 0,04) and IL-8 (Median 0.34 pg/ml to 1.42 pg/ml
after viral infection, p = 0,04) in BALF after rhinovirus
exposure [21]. However the fold changes from baseline
after infection did not change significantly between both
groups (ECP p = 0,10 and for IL-8 p = 0,10). Spearman
correlations were calculated to explore possible associa-
tions between haemostatic and inflammatory markers. At
baseline, both FGT and TATc showed a weak correlation
with IL-8 (RIL-8 = −0.455 for FGT (p = 0.03) and RIL-8 =
0.461 for TATc, both p = 0.02). No correlations were
found for ECP nor for MPO. After viral infection, the fold
changes of FGT and TATc in BAL-fluid showed a signi-
ficant correlation with ECP and MPO, while TATc alsools n = 11 Mild asthma n = 13 p-value
) 6 (46) 0.02
31) 22 (19–29) NS
) 3 (23) NS
2.41 (1.29-4.48) <0.001
.9) 70.0 (36.8) <0.05
121) 101 (80–123) NS
127) 104 (83–129) NS
) 11 (85) NS
) 7 (54) NS
) 11 (85) NS
Fraction of exhaled Nitric oxide; PC20, provocative concentration of inhaled
; pb, post bronchodilator.
Table 2 Haemostatic proteins in plasma
Median levels of haemostatic proteins in plasma
Baseline After viral infection
Control n = 11 Asthma n = 13 p-value
between groups
at baseline
Control n = 11 Asthma n = 13 p-value between
groups after
viral infection
Markers of coagulation
TATc (ng/mL) 2.4 (1.5–4.0) 1.5 (1.4–1.5) 0.02 1.95 (1.6–2.3) 1.4 (1.3–1.5) 0.03
vWF (% of pooled plasma) 77.0 (60.0–89.0) 99.0 (84.0–127.0) 0.07 87.0 (65.0–148.0) 127.0 (87.0–148.0) 0.19
D-dimer (ng/mL) 221 (112–422) 146 (127–173) 0.39 143 (113–317) 163 (144–230) 1.00
ETP (nM.min) 1653 (1340–1663) 1446 (1290–1644) 0.25 1660 (1351–1743) 1494 (1321–1645) 0.19
Markers of fibrinolysis
PAP (ng/mL) 385 (261–618) 327 (276–391) 0.17 534 (311–786) 320 (303–467) 0.047
PAI-1 (ng/mL) 13.0 (11.0–21.0) 16.0 (12.0–24.0) 0.28 11.5 (9.0–16.0) 26.0 (15.0–33.0)* 0.04
Numbers are medians with IQR in parentheses.
von Willebrand factor is expressed as percentage of normal pool plasma.
*p < 0,05 versus baseline.
Figure 2 Fold changes in haemostatic proteins and endogenous thrombin test in venous plasma after RV16-infection. Plasma levels in
healthy (white) and asthmatic (grey) individuals. of A: vWF, B: TATc, C: F: ETP, D: D-dimer, E: PAP-complexes, F: PAI-1. Box and Whisker diagram
with medians and interquartile ranges.
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Table 3 Haemostatic proteins and fibrin generation test in BAL-fluid
Median levels of haemostatic proteins in BAL-fluid
Baseline After viral infection
Control n = 10 Asthma n = 13 p-value between
groups at baseline
Control n = 11 Asthma n = 12 p-value between groups
after viral infection
FGT (s) 693 (486–853) 706 (513–855) 0.88 636 (541–859) 498 (399–596)* 0.053
TATc (ng/mL) 0.70 (0.25-4.43) 0.80 (0.50-2.10) 0.85 0.50 (0.25-0.60) 0.75 (0.53-2.73) 0.058
PAP (ng/mL) 34.5 (30.0-53.0) 44.0 (37.0-45.5) 0.15 34.0 (30.0-55.0) 42.5 (38.3-47.0) 0.14
Numbers are medians with IQR in parentheses.
*p < 0,05 versus baseline.
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these associations are shown in the Additional file 2.
Associations between RV-load in BAL fluid and
haemostatic proteins in plasma and BAL fluid
RV-16 was detected in BAL fluid in 7 asthmatic patients
and 3 healthy controls. Only the mild asthmatic patients
were analysed as the group of healthy controls was too
small. ETP showed a significant linear correlation with
RV16-load in BAL fluid (Figure 4, R2 = 0.7409 p = 0.01).
PAI-1 also showed a significant positive linear correlation
with RV16-load (R2 = 0.8559, p = 0.003), while an inverse
linear correlation with PAPc was found (R2 = 0.5283,
p = 0.06). vWF did not show a significant correlation, be-
cause of a single outlier (Figure 4A, R2 = 0,1176, p = 0,46)
When the outlier was omitted from the analyses, the rela-
tionship was very significant (R2 = 0.982, p = 0,0001). The
fold change in TATc and D-dimer did not correlate in
these patients with the RV16-load in BAL fluid, nor did
the haemostatic markers in BAL fluid correlate with the
viral load in BAL fluid.Figure 3 Fold changes in haemostatic proteins and fibrin generation
and asthmatic (grey) individuals of A: FGT, B: TATc, C: PAPc. Box and WhiskDiscussion
This study shows that rhinovirus infection in patients
with mild asthma, but not in healthy subjects, increases
procoagulant activity in the pulmonary environment as
evidenced by increased microparticle-associated TF activ-
ity (FGT) in BAL fluid. Moreover, fold changes in eosino-
phil cationic protein and myeloperoxidase were both
associated with the fold changes in FGT and TATc levels
in BAL fluid after viral infection. This suggests that rhino-
virus infection increases the local procoagulant activity in
the airways through both eosinophilic and neutrophilic
airway inflammation. In addition to local procoagulant ac-
tivity, RV16-load showed linear correlations with markers
of fibrinolysis and haemostatic activity in plasma.
This is the first study investigating the effect of expe-
rimental virus infection on activation of coagulation in
patients with asthma. We observed an increase in the
intrinsic capability to coagulate in BAL fluid, which is as-
sociated with eosinophilic and neutrophilic inflammation.
This confirms previous studies showing that inflammatory
and allergic asthma exacerbations induce coagulation intest in BAL-fluid after RV16-infection. BALF levels in healthy (white)
er diagram with medians and interquartile ranges.
Table 4 Correlations between fold changes of inflammatory
and haemostatic parameters in BAL-fluid after viral
infection
Spearman’s correlation coefficient
Fold changes
FGT TATc PAP
Eosinophils −0.103 0.363 0.190
ECP −0.517* 0.465* 0.233
Neutrophils −0.434* 0.632** 0.217
MPO −0.528* 0.806*** 0.370
IL-8 −0.413 0.579** −0.006
Significance level: *< 0.05; **< 0.01; ***< 0.001.
MPO myeloperoxidase; ECP eosinophili cationic protein; FGT fibrin generation
test; TATc thrombin-antithrombin complex; PAP plasmin-antiplasmin complex.
Figure 4 Fold changes in haemostatic proteins and endogenous thro
A: vWF, B: ETP, C: PAI-1 and D: PAPc. Scatter-dot diagram with interpolatio
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activity and factor Xa [24-34]. Both fibrin and thrombin
have been implicated in airway hyperresponsiveness and
allergic airway inflammation [35], which may be the result
of inactivation of surfactant and/or the formation of
sputumplugs [36].
The increase in procoagulant activity in patients with
asthma after rhinovirus infection can be explained by
several mechanisms. Firstly, coagulant TF-exposing mi-
croparticles are likely to play a key role in the local
activation of coagulation in the airways of asthmatic
individuals, since these microparticles have been shown
to be indispensable to initiate coagulation through the
extrinsic pathway [22]. Besides activation of coagulation,
microparticles have been shown to be mediators of in-
flammation during infection [6,37].mbin test in venous plasma versus RV-16 load in BAL fluid.
n line. (*p < 0.05, **p < 0.01).
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and neutrophils have been described in related eosino-
philic diseases, like Churg Strauss vasculitis and bullous
pemphigoid [38-40]. However, eosinophils as the po-
tential source of coagulant TF-exposing microparticles
remain controversial, since TF mRNA is below the de-
tection limit in both resting and stimulated eosinophils
[41,42]. Monocytes may be able to transfer TF to micro-
particles originating from eosinophils and neutrophils.
This may explain the associations we observed in BAL-
fluid between FGT and TATc with ECP and MPO and
fits with the observation by Bouwman et al. [25] that
virus-infected monocytes show a higher TF expression.
This study extends the role of increased procoagulant
activity as described in previous studies to infectious
aetiologies of asthma exacerbation [31,32]. For example,
we observed a decreased fibrinolysis in plasma of patients
with mild asthma after RV16 infection, while markers of
fibrinolysis were undetectable in BAL fluid. In addition,
we observed linear correlations between RV16-load in
BAL-fluid and systemic PAI-1 and ETP and an inverse
correlation with systemic PAPc were found. Two possible
explanations could be provided for these differences in
plasma. First, IFN-γ treatment has been shown to de-
crease levels of PAI-1 in healthy controls [43,44]. Since
interferon production in patients with asthma has been
shown to be impaired [45-47] this might explain the
increased levels of PAI-1 in the present study. Although
systemic fibrinolysis is impaired in patients with mild
asthma, TATc levels in plasma were higher in healthy
control subjects, while the systemic fold changes from
baseline in TATc, ETP, vWF and PAI-1 are increased in
the mild asthmatic group. A possible explanation may
be that there is no suitable trigger at baseline leading to
decreased TATc levels in plasma of patients with mild
allergic asthma. Whether there are compensatory mecha-
nisms leading to lower TATc levels in plasma of asthmatic
individuals as compared to healthy individuals is as yet
unknown and may be subject for further research. It is
important to note that after infection with a mild rhino-
virus infection the changes from baseline in plasma are
larger in the mild asthma group than in the healthy group
and illustrates the increased capability for coagulation.
Secondly, the linear correlations between RV16-load in
BAL-fluid and systemic PAI-1 and ETP and inverse
correlation with systemic PAPc observed for patients
with mild asthma point towards endothelial activation
by RV16. vWF and PAI-1 are stored in endothelial cells
[48]. Quiescent endothelial cells are generally driving the
haemostatic balance in favour of fibrinolysis through
activated protein C generation and production of tissue-
type plasminogen activator. Upon a stimulus, for example
an infection, this balance is changed into a procoagulant
state by release of amongst others vWF and expression ofPAI-1 [48,49]. Our current study points towards activation
of endothelial cells by rhinovirus, although it is unclear
whether the activation is directly or indirectly. Endothelial
cells express intercellular adhesion molecule 1 (ICAM-1),
which is not only an important molecule for leukocyte ad-
hesion [48], it is also the receptor for rhinovirus to infect
human cells [50]. However, the linear correlation between
rhinovirus in the airway lumen and procoagulant activity
in plasma points towards indirect activation of endothelial
cells by rhinovirus, for example through an inflammatory
mediators produced by airway epithelial cells [50]. Either
way, activation of the endothelium results in an increase
of PAI-1 and vWF. The increase in PAI-1 may explain the
decrease in PAPc [51], while the increase in ETP might be
explained by the increased levels of factor VIII [3,52]
commonly associated with an increase in vWF and other
pro-coagulants [53]. Both impaired IFN production and
endothelial activation may play a role in the increased
systemic haemostatic activity found in patients with mild
asthma. Our results are in line with previous studies about
the activation of haemostasis in healthy controls in vitro
(viral infection of endothelial cells and monocytes) [54,55]
and in vivo (elderly patients with acute respiratory tract
infections) [56].
The strength of our study is the experimental design,
which provided standardized exposure and comparable
time points of post-infection sampling. In addition, the
patients were free of steroids, which may affect inflam-
matory and coagulant outcomes. However, we cannot
exclude the influence of potential confounding factors
in the present outcomes. First, the male/female ratio
was different between the two groups, with more female
subjects in the control group than in the group of
patients with asthma. Since many women used oral
contraceptives, this might have influenced coagu-
lation activity [57,58]. However, we do not think that
this factor biased our results since oral contraceptive
users were equally distributed between the two groups
and fibrinolysis was only impaired in patients with
asthma.
Secondly, we did not observe significant changes for
some relevant coagulation parameters in BAL fluid and
plasma. This might relate to the mild nature of the
experimental rhinovirus infection (i.e. low infectious
dose and mild rhinovirus strain). We used this method
to infect volunteers because it most closely resembles
the natural course of rhinovirus infection. In addition,
the procedure has been proven to be safe in patients
with mild asthma and resulted in increase in common
cold symptoms in both asthmatic and healthy individuals.
The effects on coagulation are likely more pronounced
after a rhinovirus-induced exacerbation in patients with
moderate to severe asthma or in more severe disease
exacerbations (i.e. influenza).
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coagulant parameters in BAL fluid and plasma could be
the use of short-acting beta-2-agonists. Although it is
suggested that beta-2 agonists may have a small anti-
inflammatory effect [59,60], we believe this has not
influenced our results as both groups of volunteers used
salbutamol during the spirometry test just before the
bronchoscopy with BAL.
Thirdly, the study was limited by the fact that some
haemostatic parameters were below the detection limit
in BAL fluid which could be explained by the timing of
the second bronchoscopy and/or the dilution involved
with bronchoalveolar lavage. This is a common problem
often encountered and difficult to circumvent in this
type of studies due to the dilution involved with bron-
choalveolar lavage. Still, our data provides evidence of
increased procoagulant activity in the airways of patients
with asthma after viral infection, which correlates with
inflammation, and thus matches with our hypothesis.
And finally, one could argue that a larger study popu-
lation would have shown more procoagulant activity and
systemic procoagulant changes. Based on our present
findings, we calculated that we would need more than
1000 volunteers to reach statistical significance, which is
neither ethical nor feasible. Evaluation of coagulation
after rhinovirus infection in patients with more severe
asthma would be more relevant as these patients are
more at risk for venous thromboembolism [12].
Although this study is observational in nature, the
findings of the present study may have important clinical
implications. Patients with asthma have an increased risk
of pulmonary embolism [12,13] which is associated with
asthma exacerbations [13]. Our results indicate for the
first time that even a mild rhinovirus infection in patients
with mild asthma induces procoagulant activity in the
airways and a possible systemic increase in haemostatic
activity. One could hypothesize that patients with severe
asthma have more procoagulant activity and could there-
fore be at increased risk to develop acute thromboembolic
events due to rhinovirus infections. In this perspective, it
would be required to further investigate a potential causal
relationship between coagulation and eosinophilic inflam-
mation in asthmatic airways and to further explore the
nature of TF-bearing microparticles in patients with
asthma. Furthermore, follow-up studies should focus on
activation of haemostasis in patients with moderate to
severe asthma as well as procoagulant changes induced by
influenza and respiratory syncytial virus (RSV), as both
influenza and RSV are frequently isolated in patients that
are hospitalized for their asthma exacerbation [18].
Conclusions
In conclusion we have provided evidence of local pro-
coagulant activity after rhinovirus infection in the airwaysof patients with asthma, which is associated with the in-
tensity of eosinophilic and neutrophilic airway inflamma-
tion. As rhinovirus infection is a very common trigger of
asthma exacerbations the clinical consequences of this
induction of procoagulant activity deserve further investi-
gation, in particular in patients with severe asthma who
have already an increased risk of myocardial infarction,
stroke and venous thromboembolism [12,61].
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